Eli Lilly introduced a four‑dose KwikPen for its obesity drug Zepbound, a device that holds four weekly doses in a single pen and is available through LillyDirect for self‑pay patients.
The new delivery system starts at $299 per month for the 2.5 mg dose, with higher doses capped at $449 per month, and is designed to improve convenience and adherence for patients who prefer a single pen over weekly single‑dose vials.
The launch expands Lilly’s obesity product line and strengthens its competitive position against rivals such as Novo Nordisk, reinforcing the company’s strategy of expanding access and choice for patients via LillyDirect.
"As part of our commitment to supporting people living with obesity in their weight‑management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities.
The new format is expected to differentiate Zepbound and appeal to a wider patient base, supporting the company’s broader positive momentum in its obesity franchise and its strong guidance for 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.